BridgeBio’s Attruby Challenges Pfizer’s Vyndamax Legacy in Pivotal ATTR Trial

Why It Matters

If confirmed, Attruby could erode Vyndamax’s dominance, reshaping first‑line therapy and driving higher revenues for BridgeBio. The data also signals a potential new mechanistic target—transthyretin variability—relevant to clinicians and investors.

Key Takeaways

• Attruby cut outpatient worsening heart failure risk by 40% versus placebo
• Indirect comparison shows 34% fewer cardiovascular hospitalizations vs Vyndamax
• All‑cause mortality hazard reduced 28% compared with tafamidis
• Q1 sales hit $180.6 million, up 24% year‑over‑year
• Pfizer’s Vyndamax patent extended to 2031, intensifying competition

Pulse Analysis

Transthyretin amyloid cardiomyopathy (ATTR‑CM) remains a niche yet high‑mortality condition, affecting an aging population with limited therapeutic options. While Pfizer’s Vyndamax has long been the standard of care, the disease’s complex pathophysiology—misfolded transthyretin aggregating in cardiac tissue—has spurred biotech firms to pursue more potent stabilizers. BridgeBio’s Attruby, a small‑molecule stabilizer, entered the market after FDA approval in late 2024, positioning itself as a direct competitor in a market projected to exceed $1 billion globally.

The newly presented ATTRibute‑CM trial data adds a mechanistic layer to Attruby’s clinical profile. By maintaining wild‑type transthyretin concentrations and reducing protein variability, the drug appears to modulate a key driver of disease progression. The trial reported a 40% reduction in outpatient worsening heart‑failure events and a 34% cut in cardiovascular hospitalisations when compared indirectly with Vyndamax, while preserving a comparable safety record. Moreover, a 28% lower all‑cause mortality hazard suggests a survival benefit that could sway prescribers toward first‑line use, especially as physicians seek therapies that address both symptom burden and long‑term outcomes.

Commercially, the implications are significant. Attruby’s $180.6 million Q1 revenue—up 24% YoY—signals strong uptake despite Vyndamax’s extended patent protection until 2031. The indirect efficacy advantage may encourage payers to favor Attruby, potentially reshaping formulary decisions. Meanwhile, Pfizer’s settlement to delay generic competition adds a defensive layer for Vyndamax, but also highlights the competitive pressure BridgeBio now exerts. Investors will watch upcoming head‑to‑head trials and the pipeline activity of rivals such as Ionis, Novo Nordisk, and Intellia, which could further fragment the ATTR‑CM space. BridgeBio’s momentum suggests it is poised to capture a larger share of a market hungry for more effective, disease‑modifying options.